Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Western blot [1]
- Immunocytochemistry [1]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 710022 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- BMP-2 Recombinant Polyclonal Antibody (18HCLC)
- Antibody type
- Polyclonal
- Antigen
- Other
- Description
- This antibody is predicted to react with mouse based on sequence homology.
- Antibody clone number
- 18HCLC
- Concentration
- 0.5 mg/mL
Submitted references The tyrosine kinase inhibitor nilotinib targets the discoidin domain receptor DDR2 in calcific aortic valve stenosis.
Carracedo M, Pawelzik SC, Artiach G, Pouwer MG, Plunde O, Saliba-Gustafsson P, Ehrenborg E, Eriksson P, Pieterman E, Stenke L, Princen HMG, Franco-Cereceda A, Bäck M
British journal of pharmacology 2022 Oct;179(19):4709-4721
British journal of pharmacology 2022 Oct;179(19):4709-4721
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of BMP-2 in HeLa cell lysate (30 µg/lane) using a BMP-2 Recombinant Rabbit Polyclonal Antibody (Product # 710022) at a dilution of 5 µg/mL. NBT/BCIP was used as the substrate (Product # WB7105).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunofluorescence analysis of BMP-2 was done on 70% confluent log phase MCF7 cells. The cells were fixed with 4% paraformaldehyde for 15 minutes, permeabilized with 0.25% Triton™ X-100 for 10 minutes, and blocked with 5% BSA for 1 hour at room temperature. The cells were labeled with BMP-2 (18HCLC), Recombinant Rabbit Polyclonal Antibody (Product # 710022) at 1 µg/mL in 1% BSA and incubated for 3 hours at room temperature and then labeled with Goat anti-Rabbit IgG (H+L) Superclonal™ Secondary Antibody, Alexa Fluor® 488 conjugate (Product # A27034) at a dilution of 1:2000 for 45 minutes at room temperature (Panel a: green). Nuclei (Panel b: blue) were stained with SlowFade® Gold Antifade Mountant with DAPI (Product # S36938). F-actin (Panel c: red) was stained with Alexa Fluor® 555 Rhodamine Phalloidin (Product # R415, 1:300). Panel d is a merged image showing Cytoplasmic localization. Panel e is a no primary antibody control. The images were captured at 60X magnification.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- 2 FIGURE Effects of nilotinib on human valvular interstitial cells. (a) Quantification of phosphate-induced calcification of human valvular interstitial cells (VICs) after 9 days. (b) mRNA expression of the osteogenic transcription factor RUNx-2 in VICs treated for 24 h. (c) Immunoblotting against BMP-2 in human VICs after 24 h treatment with control (DMSO), nilotinib (10 muM), or imatinib (10 muM). (d) Immunoblotting against LC3-I and LC3-II in human VICs treated for 2 h with or without bafilomycin (100 nM) followed by 24 h with control (DMSO), nilotinib (10 muM), or imatinib (10 muM). (e) VIC viability after inhibition of autophagy with bafilomycin (B+) (100 nM) or vehicle control (B-) (DMSO) for 2 h, followed by treatment with control (DMSO), nilotinib (10 muM) or imatinib (10 muM) for 24 h. Data are represented as mean +- S.D. Statistical significance of differences between groups were determined when at least n = 5 (d and e). * P < 0.05 Student's t test. Each dot represents one patient VIC donor
